Rachel McMinn - 26 Mar 2025 Form 4 Insider Report for Neurogene Inc. (NGNE)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: NGNE
Reported as of: 26 Mar 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Mar 2025, 21:27:40 UTC
Prior SEC filing: 25 Nov 2024
Next SEC filing: 24 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Christine Mikail, as attorney-in-fact for Rachel McMinn

Key filing fact

Rachel McMinn filed Form 4 for Neurogene Inc. (NGNE) on 28 Mar 2025.

Key facts

This page summarizes Rachel McMinn's Form 4 filing for Neurogene Inc. (NGNE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 28 Mar 2025, 21:27.

Change

Previous filing in this sequence was filed on 25 Nov 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NGNE transaction

Common Stock

Award

Transaction value: $0
Shares: +23,900
Change %: +1.9%
Price: $0.000000
Shares after: 1,274,259
Date: 26 Mar 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NGNE transaction Derivative

Employee Stock Option (Right to buy)

Award

Transaction value: $0
Shares: +143,500
Change %
Price: $0.000000
Shares after: 143,500
Date: 26 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 143,500
Exercise price: $16.14
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Consist of 23,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.

Footnote F2

This option represents the right to purchase 143,500 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.